Rege Nephro
Japan - KyotoBiotechnology
Focus: Rege Nephro is a Japan-based biotech company focused on small molecules, cell therapy, and vesicle-based therapeutics in gene and cell therapy spaces. The company is publicly traded but operates as a specialized biotech player with a narrow pipeline.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About Rege Nephro
AI assessmentNot HiringNo open roles listed right now. Follow Rege Nephro to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Phase 2
Clinical Trials (1)
NCT06289998Study of Tamibarotene in Patients With ADPKD
Phase 2Help build intelligence for Rege Nephro
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.